Join The Conversation Card Front 01 Copy

The Medtechy Daily: October 5

Posted on October 05, 2018 Share This Article:


The Medtechy Daily provides the latest news and insight for the medical technology industry, including medical device, biotech and digital health.

Tweets of the Day

Headlines 

Will Single Port Robots Revive the Perineal Radical Prostatectomy? Designing a robotic-assisted surgery system that brings four robotic arms through a single 25mm port was far from an easy feat for Intuitive Surgical. In a recent interview with MD+DI, Intuitive's chief operating officer described it as a tremendous learning challenge that took the company on a 12-year journey. (MDDI)

"When it was done many years ago open it was cumbersome to do, and that's why it was almost abandoned," Kaouk told MD+DI. "So this new system, requiring only a tiny incision to insert all instruments, gives us a revived hope that we may again revisit the perineum approach from between the legs, and that's where the procedure becomes significantly less morbid and patients will enjoy a quicker recovery. So that is the potential of this system down the road."

Cleveland Clinic is First in the U.S. to Perform Prostate Surgery Using Intuitive Surgical's Single Port SP Robot. Late last week, Cleveland Clinic became the first hospital in the country to successfully perform surgeries using the Intuitive Surgical Single Port SP Robot, which inserts all surgical instruments through one small abdominal incision, improving surgical outcomes and allowing quicker patient recovery. (Medtechy)

AtriCure posts Street-topping Q3 prelims. AtriCure (NSDQ:ATRC) late yesterday released preliminary earnings for the third quarter that beat consensus on Wall Street. (MassDevice)

A Republican lobbying firm is behind Washington’s newest pro-pharma advocacy group. A Republican lobbying firm, the CGCN Group, is behind this week’s launch of the shadowy drug pricing organization, Alliance to Protect Medical Innovation, a partner at the firm confirmed to STAT.(STAT)

Lilly's diabetes drug data impresses, hurts rival Novo's shares. Eli Lilly and Co LLY said on Thursday its new two-in-one diabetes drug was successful in lowering blood sugar and reducing weight, sending its shares to a record high and weighing on those of arch-rival Novo Nordisk.(Reuters)

How Doctors Can Be Better Mentors. Being a good doctor is a lot like being a good mentor. Just as clinicians have an ethical duty to act in the best interest of their patients, mentors have a similar duty towards their mentees.(Harvard Business Review)

Owlstone Advances Breath Biopsy Platform with $50M Round. Owlstone Medical has raised a total of $50 million for its Breath Biopsy platform. The Cambridge, England-based company said it has raised about $73 million since it was founded in 2016. (MDDI)